Apixaban for the Reduction of Thromo-Embolism in Patients with Device-Detected Sub-Clinical Atrial Fibrillation
The main purpose of the ARTESiA study, is to determine if the use of apixaban in patients with sub-clinical atrial fibrillation (SCAF) will reduce the incidence of stroke and systemic embolism compared to aspirin.
PI: Dr. Molly Sachdev
Study Coordinators: Linda Schimmoeller and Becca Kammer
This study is currently enrolling. To learn more about ARTESiA and how you can join contact our research office at (314) 289-7690.